Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
New England Journal of Medicine · 23.07.2026 · 395 (4) · 338-348
DOI: 10.1056/nejmoa2601486 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 23.07.2026. Verfasst von Matthew D Galsky und 27 weiteren Autor:innen. Beteiligte Einrichtung: Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Cystectomy. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: Seagen Inc., Bothell, WA, USA, which was acquired by Pfizer in Dec. 2023, Astellas Pharma Inc., Northbrook, IL, USA, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant cisplatin-based chemotherapy is a standard therapy for muscle-invasive bladder cancer. The efficacy and safety of neoadjuvant and adjuvant (perioperative) enfortumab vedotin-pembrolizumab as compared with neoadjuvant cisplatin-based chemotherapy in persons with this cancer are unclear. METHODS: We conducted a phase 3, open-label, randomized trial involving adults with muscle-invasive bladder cancer eligible for cisplatin-based chemotherapy and radical cystectomy with pelvic lymph-node dissection (cystectomy). Participants were assigned to receive neoadjuvant enfortumab vedotin-pembrolizumab (4 cycles; enfortumab vedotin [1.25 mg per kilogram of body weight on days 1 and 8] and pembrolizumab [200 mg on day 1] every 3 weeks), cystectomy, and 5 cycles of enfortumab vedotin and 13 cycles of pembrolizumab as adjuvant therapy or to receive neoadjuvant cisplatin-gemcitabine (4 cycles; cisplatin [70 mg per square meter of body-surface area on day 1] plus gemcitabine [1000 mg per square meter on days 1 and 8] every 3 weeks) and cystectomy. The primary end point was event-free survival; key secondary end points were overall survival and pathological complete response. Safety was assessed. RESULTS: A total of 405 participants were assigned to receive enfortumab vedotin-pembrolizumab and 403 to receive cisplatin-gemcitabine. The median time from randomization to the data-cutoff date was 33.6 months (range, 22.5 to 53.6). A total of 86.7% of the participants in the enfortumab vedotin-pembrolizumab group and 89.6% of those in the cisplatin-gemcitabine group underwent cystectomy. At 2 years, estimated event-free survival was 79.4% with enfortumab vedotin-pembrolizumab and 66.2% with cisplatin-gemcitabine (hazard ratio for an event or death, 0.53; 95% confidence interval [CI], 0.41 to 0.70; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai, New York.
- Hospital Universitario Virgen del Rocío, Seville, Spain.
- Istituto Oncologico Veneto (IOV)-IRCCS, Padua, Italy.
- Catalan Institute of Oncology Badalona, Badalona Applied Research Group in Oncology, Translational Program in Cancer Research, Institut Germans Trias i Pujol, Barcelona.
- Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca, Cluj-Napoca, Romania.
- University of Florida, Gainesville.
ORCID-Profile: Alfonso Gómez de Liaño
Förderung
- Seagen Inc., Bothell, WA, USA, which was acquired by Pfizer in Dec. 2023
- Astellas Pharma Inc., Northbrook, IL, USA
- Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Zitieren
APA
Galsky, M. D., Valderrama, B. P., Maruzzo, M., Font, A., Ciuleanu, T., Chatzkel, J., Koie, T., Hoimes, C. J., Puente, J., Zakharia, Y., Rosenbaum, E., Boehm, K., Loriot, Y., Bedke, J., Powles, T. B., Necchi, A., Wiechno, P., Álvarez-Fernández, C., Kim, T. H., …, & KEYNOTE-B15/EV-304 Investigators (2026). Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. New England Journal of Medicine, 395(4), 338-348. https://doi.org/10.1056/nejmoa2601486
Vancouver
Galsky MD, Valderrama BP, Maruzzo M, Font A, Ciuleanu T, Chatzkel J, et al. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer. New England Journal of Medicine. 2026;395(4):338-348. doi:10.1056/nejmoa2601486
BibTeX
@article{Galsky2026,
author = {Galsky, Matthew D and Valderrama, Begoña P and Maruzzo, Marco and Font, Albert and Ciuleanu, Tudor and Chatzkel, Jonathan and Koie, Takuya and Hoimes, Christopher J and Puente, Javier and Zakharia, Yousef and Rosenbaum, Eli and Boehm, Katharina and Loriot, Yohann and Bedke, Jens and Powles, Thomas B and Necchi, Andrea and Wiechno, Pawel and Álvarez-Fernández, Carlos and Kim, Tae-Hwan and Oliveira, Niara and Flaig, Thomas W and Wirtz, Heidi S and Mihm, Michael and Huang, Qinlei and Rogiers, Aljosja and Homet Moreno, Blanca and Gómez de Liaño, Alfonso and KEYNOTE-B15/EV-304 Investigators, KEYNOTE-B15/EV-304 Investigators},
title = {Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer},
journal = {New England Journal of Medicine},
year = {2026},
volume = {395},
number = {4},
pages = {338--348},
doi = {10.1056/nejmoa2601486}
}
EUVIMED